Now available APHEXDA™

APHEXDA™ (motixafortide) for injection, for subcutaneous use, is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Please see full prescribing information here.